Gyre Therapeutics Inc GYRE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GYRE is a good fit for your portfolio.
News
-
Gyre Wins China Approval for Tablet to Treat Thrombocytopenia
-
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
-
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
-
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
-
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
-
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $12.04
- Day Range
- $11.50–12.45
- 52-Week Range
- $4.80–30.40
- Bid/Ask
- $10.75 / $19.32
- Market Cap
- $1.03 Bil
- Volume/Avg
- 48,441 / 77,132
Key Statistics
- Price/Earnings (Normalized)
- 31.98
- Price/Sales
- 7.55
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 391
- Website
- https://www.gyretx.com
Valuation
|
Metric
|
GYRE
|
|---|---|
Price/Earnings (Normalized) | 31.98 |
Price/Book Value | 18.22 |
Price/Sales | 7.55 |
Price/Cash Flow | 44.55 |
Price/Earnings
GYRE
Financial Strength
|
Metric
|
GYRE
|
|---|---|
Quick Ratio | 2.78 |
Current Ratio | 3.22 |
Interest Coverage | — |
Quick Ratio
GYRE
Profitability
|
Metric
|
GYRE
|
|---|---|
Return on Assets (Normalized) | 23.51% |
Return on Equity (Normalized) | 59.79% |
Return on Invested Capital (Normalized) | 39.52% |
Return on Assets
GYRE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Pxvscfrtdk | Qnrt | $636.9 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dlprrhw | Tjycqhh | $122.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tybrfmtw | Nzqhb | $115.1 Bil | |||
| Moderna Inc
MRNA
| Sfytmrsl | Ykhhs | $44.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Chkthdwq | Shgvrx | $31.3 Bil | |||
| argenx SE ADR
ARGX
| Hndhnyqnx | Kyt | $26.2 Bil | |||
| BioNTech SE ADR
BNTX
| Qpkcbqzf | Btn | $19.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dvljkfkq | Mgbpxs | $15.6 Bil | |||
| United Therapeutics Corp
UTHR
| Kqqsxxcnr | Dcgjx | $14.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Sywvtkjd | Dmvys | $11.7 Bil |